Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms

被引：0
作者：
Gudbjörg Sigurjonsdottir
Tommaso De Marchi
Anna Ehinger
Johan Hartman
Ana Bosch
Johan Staaf
Fredrika Killander
Emma Niméus
机构：
[1] Lund University,Division of Oncology, Department of Clinical Sciences Lund
[2] Skåne University Hospital,Department of Oncology and Radiation Physics
[3] Laboratory Medicine,Department of Clinical Genetics, Pathology and Molecular Diagnostics
[4] Region Skåne,Department of Oncology and Pathology
[5] Karolinska Institute and University Hospital,Division of Translational Cancer Research, Department of Laboratory Medicine
[6] Lund University,Divison of Surgery, Department of Clinical Sciences Lund
[7] Medicon Village,Department of Surgery
[8] Lund University,undefined
[9] Skåne University Hospital,undefined
来源：
Breast Cancer Research | / 25卷
关键词：
Triple-negative breast cancer; PD-L1; Immunohistochemistry; SP142; 22C3; Concordance; TILs; Patient outcome; Gene expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 247 条
  • [1] Li X(2017)Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer Breast Cancer Res Treat 161 279-287
  • [2] Yang J(2023)Role of immunotherapy in breast cancer JCO Oncol Pract 24 e1055-e1069
  • [3] Peng L(2019)Programmed cell death ligand 1 in breast cancer: technical aspects, prognostic implications, and predictive value Oncologist 22 38-2121
  • [4] Sahin AA(2021)Predictive biomarkers of immune checkpoint inhibitor response in breast cancer: looking beyond tumoral PD-L1 Biomedicines 379 2108-1828
  • [5] Huo L(2021)Biomarkers of immune checkpoint blockade response in triple-negative breast cancer Curr Treat Options Oncol 396 1817-1100
  • [6] Ward KC(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med 396 1090-821
  • [7] Jacob SL(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 382 810-1004
  • [8] Huppert LA(2021)Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Lancet Oncol 32 994-66
  • [9] Rugo HS(2020)Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Lancet 27 59-543
  • [10] Miglietta F(2020)Pembrolizumab for early triple-negative breast cancer N Engl J Med 33 534-567
12345678910